



# Role of PET gamma detection in radioguided surgery: a systematic review

Maria Silvia De Feo<sup>1</sup> · Viviana Frantellizzi<sup>1</sup> · Luciano De Sio<sup>2</sup> · Alessio Farcomeni<sup>3</sup> · Giuseppe De Vincentis<sup>1</sup> · Roberto Pani<sup>2</sup>

Received: 14 February 2023 / Accepted: 22 March 2023  
© The Author(s) 2023

## Abstract

**Purpose** This systematic review aimed to collect published studies concerning intraoperative gamma detection of positron-emitting tracers for radioguided surgery (RGS) applications.

**Methods** A systematic literature search of studies published until October 2022 was performed in Pubmed, Web Of Science, Central (Cochrane Library) and Scopus databases, including the following keywords: “Positron Emission Tomography” OR “PET” AND “Gamma” OR “ $\gamma$ ” AND “Probe” AND “Radioguided Surgery” OR “RGS”. The included studies had to concern RGS procedures performed in at least 3 patients, regardless of the administered radiopharmaceutical and the field of application.

**Results** Among to the 17 selected studies, all published between 2000 and 2022, only 2 investigations were conducted with gallium-68 (<sup>68</sup>Ga)-labeled somatostatin analogues, with fluorine-18-fluoro-2-deoxyglucose ([<sup>18</sup>F]FDG) being the most commonly used agent for RGS applications. Almost all studies were performed in oncologic patients, with only one paper also including inflammatory and infectious findings. The analysis showed that the largest part of procedures was performed through the intraoperative use of conventional gamma probes, not specifically designed for the detection of annihilation photons ( $n=9$ ), followed by PET gamma probes ( $n=5$ ) and with only three studies involving electronic collimation.

**Conclusions** Regardless of the intraoperative devices, RGS with positron emitters seems to lead to significant improvements in surgeons’ ability to obtain a complete resection of tumors, even if the nature of photons resulting from positron–electron collision still remains extremely challenging and requires further technical advances.

**Keywords** PET gamma detection · Radioguided surgery · Gamma-probe · FDG

## Abbreviations

RGS	Radioguided surgery	PRISMA	Preferred Reporting Items for Systematic reviews and Meta-analyses
PET	Positron emission tomography	CASP	Critical Appraisal Skills Programme
<sup>18</sup> F	Fluorine-18	<sup>68</sup> Ga	Gallium-68
FDG	Fluoro-2-deoxyglucose	ROLL	Radioguided occult lesion localisation
TBR	Tumor-to-background ratio	GLUT 1 and GLUT 3	Glucose transporter-1 and 3
		<sup>99m</sup> Tc	Technetium-99m
		<sup>111</sup> In	Indium-111
		<sup>123</sup> I	Iodine-123
		<sup>125</sup> I	Iodine-125
		GEP-NETs	Gastroenteropancreatic neuroendocrine tumors
		FDOPA	Fluorodihydroxyphenylalanine

✉ Viviana Frantellizzi  
viviana.frantellizzi@uniroma1.it

<sup>1</sup> Department of Radiological Sciences, Oncology and Anatomic-Pathology, Sapienza University of Rome, Rome, Italy

<sup>2</sup> Department of Medico-Surgical Sciences and Biotechnologies—Research Center for Biophotonics, Sapienza University of Rome, Latina, Italy

<sup>3</sup> Department of Economics & Finance, University of Rome “Tor Vergata”, Rome, Italy

## Introduction

Radioguided surgery (RGS) represents an interventional nuclear medicine procedure enabling surgeons to identify lesions at increased radiopharmaceutical concentration through the intraoperative use of radiation detectors [1]. Providing real-time information regarding the location and the extent of disease, allowing for the assessment of surgical resection margins, as well as minimizing the invasiveness of many diagnostic and therapeutic procedures, RGS has gained increasing acceptance over the years, becoming an established discipline within the practice of surgery and revolutionizing the surgical management of many malignancies, as well as the surgical approach to parathyroid disease. From simple Geiger Müller tubes [2, 3] intraoperative detection devices have consequently evolved to sophisticated and ergonomical hand-held probes, providing surgeons numerical, graphical, and acoustical feedback proportionally correlated to radiopharmaceutical concentration and suiting specific surgical applications, including laparoscopic procedures [3]. According to the type of detected radiation, the main categories of intraoperative detectors are represented by gamma probes and beta probes, the formers detecting photon radiation of gamma and X-rays, the latter detecting either positively ( $\beta^+$ , positrons) or negatively ( $\beta^-$ ) charged electrons [4, 5]. In the last decades, there has been increased interest and growth in clinical research concerning the possible use of positron emission tomography (PET) radiopharmaceuticals for RGS applications. In particular, fluorine-18-fluoro-2-deoxyglucose ( $^{18}\text{F}$ )FDG has become an extremely useful tool in oncology and has consequently opened new expectations for radical surgery, becoming the most studied positron-emitting tracer for RGS applications. Positrons emitted from proton-rich/neutron-deficient isotopes travel a short distance of several millimeters within tissues before interacting with negatively charged electrons and annihilating [6], making radio guidance purposes with PET tracers achievable with both beta and gamma probes. The 511-keV photons resulting from annihilation and emitted at a  $180^\circ$  angle from each other, are the basis of coincidence imaging and can be identified with intraoperative photon-sensitive probes, giving a close approximation of the location of positron emission [7]. A hand-held gamma probe for intraoperative detection of positron-emitting radionuclides was first used in 1999 for  $^{18}\text{F}$ )FDG radioguided surgery in 14 patients with colorectal cancer by Desai et al. [8], dating back the earliest experiences to over 20 years ago. The detection of 511-keV photons derived from positron–electron annihilation represents an important challenge for gamma

detection systems and has been the focus of recent developments specifically intended for the innovative detection of higher energies. Probes are designed to detect differences in radioactivity released from tumor-bearing compared to adjacent normal tissues, providing surgeons a tumor-to-background ratio (TBR) comfortable with target localization [9–11]. Due to high-energy photon fluxes, making the achievement of satisfactory TBR extremely challenging, the gamma detection of positron emission for RGS purposes has not found a routine place in cancer surgery and no standard protocol has been proposed, despite the high prevalence and the cornerstone role of PET imaging in the diagnosis, staging, follow-up, surveillance and monitoring of therapies for a wide variety of malignancies [12, 13]. In this background, the literature pertaining to intraoperative gamma detection of positron-emitting isotopes results heterogeneous and the development of novel technologies is still ongoing. This systematic review aims to provide a comprehensive overview of gamma detection of positron-emitting radiopharmaceuticals for RGS applications. Particular attention was paid to the characteristics and performances of different gamma detection systems, by underlining strengths and critical issues that emerged from surgical practice.

## Materials and methods

### Search strategy and study selection

This systematic review was drawn up according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines [14]. The literature research was carried out online on Pubmed, Web Of Science, Central (Cochrane Library), and Scopus databases by applying a search strategy based on the following keywords: “Positron Emission Tomography” OR “PET” AND “Gamma” OR “ $\gamma$ ” AND “Probe” AND “Radioguided Surgery” OR “RGS”. The search included all papers published until October 2022. Reviews, book chapters, and editorials/letters were excluded. The English language was mandatory for inclusion. Eligible articles had to focus on the role of gamma probe detection of positron-emitting tracers in RGS procedures performed in humans, regardless of the administered radiopharmaceutical and the field of application. Prospective studies, feasibility studies, pilot studies, and case series with a cohort of  $\geq 3$  patients were included. The reference lists of suitable studies were carefully checked to identify any additional relevant literature.

## Data extraction and methodological quality assessment

Data extraction was retrieved for all the selected studies and included authors, location, year of publication, type of study, indication to RGS, sample size, administered radiopharmaceutical, and outcomes. Studies with incomplete technical or clinical data were considered ineligible. The methodological quality assessment was performed using the Critical Appraisal Skills Programme (CASP). Data extraction and subsequent critical appraisal were independently performed by two reviewers and eventual disagreements and discrepancies were resolved by unanimous approval after discussion among researchers.

## Results

### Search results

A total of 124 articles were found and thus screened by examining each abstract in order to identify potentially suitable studies. From the overall group of 124, 24 reviews, 5 editorials/letters, 3 book chapters, 4 articles not in English language, as well as 60 articles concerning RGS procedures other than positron-emitting radionuclides were excluded. The remaining 28 studies were assessed for eligibility with the exclusion of further 19 papers (6 case reports/case series with less than three patients, 2 dosimetric studies, 3 preclinical studies, 3 retrospective analyses, 4 articles involving  $\beta^+$  detection, 1 study with no full text available). 8 relevant manuscripts were added after examining the reference lists of suitable articles,




Fig. 1 PRISMA flow-chart

	1. Was there a clear question for the study to address?	2. Was there a comparison with an appropriate reference standard?	3. Did all patients get the diagnostic test and reference standard?	4. Could the results of the test have been influenced by the results of the reference standard?	5. Is the disease status of the tested population clearly described?	6. Were the methods for performing the test described in sufficient detail?	7. What are the results?	8. How sure are we about the results? Consequences and cost of alternatives performed?	9. Can the results be applied to your patients/the population of interest?	10. Can the test be applied to your patient or population of interest?	11. Were all outcomes important to the individual or population considered?	12. What would be the impact of using this test on your patients/population?
Desai et al. 2000	⊙	⊙	⊙	⊗	⊙	⊙	⊙	?	?	⊙	⊙	It may improve achieving complete surgical resection
Essner et al. 2001	⊙	⊙	⊙	⊙	⊙	⊙	⊙	?	?	⊙	⊗	It may be useful to assess disease status of patients considered for surgical resection of metastatic disease
Kraeber-Bodéré et al. 2005	⊙	⊙	⊙	⊙	⊙	⊙	⊗	?	?	⊙	⊗	It may be particularly useful in presence of fibrous tissue subsequent to previous operation
Nwogu et al. 2006	⊙	⊙	⊙	⊗	⊙	⊙	⊙	?	?	⊙	⊙	It may be useful in upstaging patients
Curtet et al. 2007	⊙	⊙	⊗	⊙	⊙	⊙	⊙	⊙	?	⊙	⊗	It may be relevant in case of recurrence
Sarikaya et al. 2007	⊙	⊙	⊙	⊙	⊙	⊙	⊙	?	?	⊙	⊙	It may be useful in detecting the extent of abdominal and pelvic recurrence

**Fig. 2** CASP diagnostic checklist

leading to a total of 17 articles ultimately selected for the qualitative analysis of this systematic review. The detailed study selection flow-chart, along with the search strategy and the applied selection criteria, are represented in Fig. 1.

### Methodological quality

The quality appraisal of selected studies is represented in Fig. 2. All studies satisfied at least 6 of the 11 domains, with 8 out of 17 studies satisfying 9 domains. 10 studies showed high risk in one or more domains. One of the major concerns with selected studies was the absence of adequate follow-up in most of them, limiting the evaluation of patients' outcomes. Regarding patient's selection, RGS requires accurate preoperative assessment, leading to unavoidable patient's selection, making it not always possible to consecutively enroll subjects. It was found a high concern of applicability in evaluating the possibilities of application of obtained results, as it regards heterogeneous surgical procedures. Cumulatively, the quality appraisal resulted in quite good.

### Analysis of the evidence

The 17 selected papers were published from 2000 to 2022. Most studies were conducted by authors from the USA and Europe, with only one study performed by researchers from South Korea. A major limitation of the various studies was represented by the limited number of enrolled patients ranging from 3 to 40, the latter corresponding with the prospective study by Gulec et al. [15]. 9 papers (52.9%) had a cohort < 10 subjects. As subjects were

essentially cancer patients, selected studies were about RGS applications in the oncological field, except for only one study performed by Vos et al. including patients with infectious and inflammation diseases [16]. Almost all studies were performed using [<sup>18</sup>F]FDG, with a minority of investigations ( $n=2$ ) conducted with gallium-68 (<sup>68</sup>Ga)-labeled somatostatin analogues. A positive PET scan before surgery was mandatory for addressing patients with RGS in all studies. From the analysis of the selected papers, we identified 3 main categories of gamma probes for RGS applications with positron-emitting tracers: (1) conventional gamma probes ( $n=9$ ), (2) PET gamma probes ( $n=5$ ), (3) electronically collimated gamma probes ( $n=3$ ). Tables 1 and 2 report the main characteristics of included studies and gamma probes, respectively. The findings of the selected papers for each type of gamma detector are described in the following paragraphs.

### Conventional gamma probes

Most published studies concerning RGS procedures with gamma probes for the detection of positron-emitting tracers have been performed through the intraoperative use of conventional gamma probes, not specifically designed for the detection of annihilation photons, including the two selected studies involving a radiopharmaceutical different from [<sup>18</sup>F]FDG.

Among this heterogeneous group, the most studied malignancy was represented by colorectal cancer, with two studies performed exclusively in this setting of patients and one study also included patients with melanoma in the cohort. In

**Table 1** Characteristics of included studies

Source	Year/location	Indication for RGS and sample size	Radiopharmaceutical, administered activity and time prior to surgery	TBR (background in adjacent region if not specified)	Pre-operative PET imaging	Probe utility
Desai et al.	2000/USA	Primary and recurrent colorectal cancer (14 patients)	<sup>18</sup> F]FDG 4.0–5.7 mCi 58–110 min	NA	1–32 days (not performed in one patient)	Correct identification of tumor foci in 13/14 patients, one of whom had tumor deposits in the abdominal not visualized on preoperative PET imaging; failed identification in a subject with recurrent mucin pseudomyxoma-producing tumor
Essner et al.	2001/USA	Metastatic colon cancer or melanoma (8 patients)	<sup>18</sup> F]FDG 7–10 mCi Variable, within 3 h	In vivo from 1.16:1 to 4.67:1 for patients with melanoma and from 1.19:1 to 7.92:1 for colon cancer patients	NA	Successful localization of all 17 lesions and subsequent resection of 13; probe detection of a liver metastasis visualized on ultrasound but not found by preoperative CT or PET and not palpated on inspection
Kraeber-Bodéré et al.	2005/France	Radioiodine-negative differentiated thyroid carcinoma metastases (10 patients)	<sup>18</sup> F]FDG Mean 265 MBq (range 165–526) 30 min	In vivo: T/neck 1.40 (0.76–2.59) and T/shoulder 1.73 (1.19–2.84) ex vivo: T/normal tissue 2.44 (1.18–7.89)	NA	Detection of all tumor nodules identified preoperatively and assessment of complete resection of all foci; microscopic lymph node metastases with low uptake missed in 5 patients by both preoperative imaging and gamma probe
Nwogu et al.	2006/USA	Non-small cell lung cancer (NSCLC) with lymph nodes metastasis (10 patients)	<sup>18</sup> F]FDG 10 mCi Within 4 h	NA	NA	Identification of 5 true positive patients, of which 3 negative at routine H&E but resulted positive after ultrastaging; 3 false-positive and 2 false-negative results due to inflammation and proximity to primary tumor, respectively
Curtet et al.	2007/France	Iodine-negative differentiated thyroid cancer (DTC) recurrence (7 patients)	<sup>18</sup> F]FDG Mean 211 MBq (range 165–231) 1 h	In vivo mean 1.86 (range 1.3–2.7), ex vivo mean 2.3 (range 1.5–7.9) with probe 1 In vivo mean 1.8 (range 1.5–2.5), ex vivo mean 2.1 (range 1.5–4.9) with probe 2	15–30 days prior	Detection of all target tumors, but resection of 8/13 due to inaccessibility; histopathologic finding of additional 8 small lesions not detected by imaging and probes

Table 1 (continued)

Source	Year/location	Indication for RGS and sample size	Radiopharmaceutical, administered activity and time prior to surgery	TBR (background in adjacent region if not specified)	Pre-operative PET imaging	Probe utility
Sarikaya et al.	2007/USA	Recurrent colorectal cancer (21 patients)	$^{18}\text{F}$ FDG 370–555 MBq 30 min	$1.68 \pm 0.57$ in true positive lesions; $2.36 \pm 2.50$ in false-positive lesions	16 days prior (range 1–41) in 19/21, same day in 2/21	Detection of 29/37 sites of recurrent tumor with both preoperative PET and intraoperative gamma probe; probe detection of 6 foci of less than 1 cm in the omentum and pelvis not seen on preoperative scan, but better localization of liver and distant metastases with PET; successful identification of mucinous adenocarcinoma with both techniques
Cohn et al.	2008/USA	Recurrent ovarian cancer (3 patients)	$^{18}\text{F}$ FDG 10–20 mCi 60–120 min	NA	Same day	Identification and resection of clinically occult retroperitoneal disease in patient 1, rapid recognition of the unresectable nature of the disease in patient 2, no detection of additional information with respect to known and clinically apparent lymphadenopathies in patient 3
Kaemmerer et al.	2011/Germany	Primary or recurrent gastroenteropancreatic (GEP) NETs (9 patients)	$^{68}\text{Ga}$ [Ga-DOTA-NOC or DOTATATE ~180 MBq 1.5–2 h	$9.13 \pm 4.71$	2–4 weeks prior with additional same-day acquisition of the surgical region	Detection of 94% of histologically confirmed lesions, with respect to 69% of PET/CT and 50% of surgical palpation
Sadowski et al.	2015/USA	Primary and recurrent gastroenteropancreatic (GEP) NETs (14 patients)	$^{68}\text{Ga}$ [Ga-DOTATATE Mean 5.0 mCi (range 4.09–5.33) $78.2 \pm 51.13$ min (range 10–193)	In vivo mean 4.46 (range 1.6–43.56), with background count rates obtained from liver and mesenteric or omental fat	84 days prior (range 1–214)	Highest correct identification of gastric and small bowel neuroendocrine tumors, including mesenteric lymph nodes (17 of 21, 81.0%); difficult detection of pancreatic NETs, peripancreatic lymph nodes, and liver metastasis due to high relative background counts

**Table 1** (continued)

Source	Year/location	Indication for RGS and sample size	Radiopharmaceutical, administered activity and time prior to surgery	TBR (background in adjacent region if not specified)	Pre-operative PET imaging	Probe utility
Guilec et al.	2006/USA	Heterogeneous malignancies (40 patients)	<sup>18</sup> F]FDG 7–10 mCi 1–4 h	In vivo mean 1.9 (range 1.4–2.5) Ex vivo mean 2.1 (range 1.5–3.3)	NA	Detection of all PET image-positive lesions; localization of a lesion in a previously explored field in 4 cases and detection of non-palpable lesions in 8 cases; identification of additional retroperitoneal lesions not seen on preoperative imaging study in 2 cases
Molinaa et al.	2009/USA	Heterogeneous malignancies (9 patients)	<sup>18</sup> F]FDG 10–12 mCi 3–4 h	NA	NA; after initial experiences, the persistence of [ <sup>18</sup> F]FDG avidity on a minimum of two sequential studies were required	Helpful navigating into scar tissue and confirmation of complete removal of the lesions after tumor bed activity reached the background counts; 12/14 lesions localized and removed; 2/14 lesions not identified with the probe had negative PET scans on the day of surgery; intraoperative accuracy of PET probe approximately of 100%
Kim et al.	2010/Korea	Differentiated thyroid cancer (12 patients)	<sup>18</sup> F]FDG 363 MBq (range, 227–570) 2–6 h	In vivo mean 1.51 ± 0.53 (range 1.17–4.03)	Same day	Detection of all lesions demonstrated by preoperative PET and of additional sites in 7 patients; identification of a non-palpable, metastatic lymph node not revealed by both PET and neck ultrasonography in the deep, superior mediastinum, after re-exploration of the operative bed
Orsaria et al.	2017/Italy	Breast cancer (3 patients)	<sup>18</sup> F]FDG 370–450 MBq 2–3 h	NA	Same day	Confirmation of PET imaging findings in patient 1 and localization of nodal disease not detected on preoperative imaging study in patient 3; low accuracy in the identification of nodal micrometastasis in patient 2

Table 1 (continued)

Source	Year/location	Indication for RGS and sample size	Radiopharmaceutical, administered activity and time prior to surgery	TBR (background in adjacent region if not specified)	Pre-operative PET imaging	Probe utility
Rinehardt et al.	2022/USA	Primary, recurrent or metastatic pediatric cancers (8 patients)	$^{18}\text{F}$ FDG 0.2 mCi/Kg 1 h	Ex vivo mean 4.0 (range 0.9–12), 4.7 and 2.1 in malignant and benign lesions, respectively	Within 1 month, with a median of 10 days (range 2–29)	Application limited to the ex vivo confirmation of $^{18}\text{F}$ FDG-avid tumor excision, due to poor lesion specificity for intraoperative guidance in vivo; positive pathology in 12/17 excised lesions
de Jong et al.	2010/The Netherlands	Retroperitoneal testicular tumor recurrences (3 patients)	$^{18}\text{F}$ FDG 5 MBq/Kg 3 h	$\geq 5:1$ in vivo and ex vivo	NA	Detection of all target lesions and of an additional tumor of 1.5 cm in one patient
García et al.	2011/Spain	Heterogeneous recurrent tumors (12 patients)	$^{18}\text{F}$ FDG $10 \pm 0.5$ mCi 3–5 h	From 1.5 to 2.5 in vivo	2 weeks prior	Detection and resection of 14/16 (87.5%) lesions
Vos et al.	2016/The Netherlands	Heterogeneous malignancies and infectious disease (9 patients)	$^{18}\text{F}$ FDG 3.5 MBq/Kg 4 h	NA	Same day	Successful identification and excision of all target lesions

NA not applicable

2000, Desai and colleagues published their work involving 14 patients with primary or recurrent colorectal cancer [17]. Desai et al. reported successful results in all but one patient with recurrent mucin pseudomyxoma-producing tumor and underlined the additional detection of tumor deposits in the abdominal not visualized on preoperative PET imaging obtained in one subject. Their paper also included a preclinical evaluation of probe performances and a phantom study in peritoneal models. In 2007, Sarikaya et al. reported probe detection of 6 foci of less than 1 cm in the omentum and pelvis not seen on preoperative scan, as well as the successful identification of mucinous adenocarcinoma with both techniques, but underlined the superiority of PET imaging in the localization of liver (Fig. 3) and distant metastases [18]. On the other hand, after the in vitro analysis of the gamma probe, in 2001, Richar Essner and coworkers had successfully tested its detection capabilities in six melanoma and two colon carcinoma patients and reported how the probe managed to detect a liver metastasis visualized on ultrasound but not found by preoperative CT or PET and not palpated on inspection [19]. Conventional gamma probe performances have also been evaluated in patients with radioiodine-negative differentiated thyroid carcinoma in two different studies both performed by French Authors. In 2005, Kraeber-Bodéré and colleagues demonstrated the successful identification of all lesions reported on preoperative imaging in all ten enrolled patients but reported how five patients had additional microscopic lymph node metastases with low uptake missed by both preoperative imaging and gamma probe [20]. Similar findings were subsequently reported by Curtet et al., in a comparative study performed with two different conventional gamma probes, one with a bismuth germanate (BGO) crystal, and the other with a thallium-activated caesium iodide (CsI(Tl)) scintillating crystal, both previously tested in vitro and both failing in detecting small additional lesions revealed through histopathologic examination [21]. In 2006, Nwogu and coworkers tested the capability of a conventional gamma probe in identifying metastatic lymph nodes in ten patients with Non-Small Cell Lung Cancer (NSCLC) [22]. In particular, they focused on the role of RGS in detecting micrometastases, thus resulting in upstaging of patients. Three out of five positive findings were negative at routine H&E but resulted positive after ultrastaging, demonstrating the capability of the gamma probe in identifying micrometastasis. However, Nwogu et al. reported three false-positive and two false-negative results, due to inflammation and proximity to the primary tumor, respectively. A case series of three recurrent ovarian cancer patients was published in 2008 by Cohn et al. reported the detection of additional retroperitoneal metastasis obtained with a conventional device in one patient [23]. Two studies were performed in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) using  $^{68}\text{Ga}$ -labeled



somatostatin analogs. One of the main concerns in this setting of patients is represented by recurrent laparotomies leading to multiple adhesions and altered anatomy, which make extremely challenging the localization of malignant tissues and thus RGS particularly useful. In 2011, Kaemmerer et al. published a pilot study involving nine patients with primary or recurrent GEP-NETs using either [ $^{68}\text{Ga}$ ]Ga-DOTANOC and [ $^{68}\text{Ga}$ ]Ga-DOTATATE [24]. Subsequently, Sadowski and colleagues tested the performances of a conventional gamma probe in detecting [ $^{68}\text{Ga}$ ]Ga-DOTATATE avid lesions in a cohort of 14 patients with GEP-NETs [25].

### PET gamma probes

Among the overall group of selected studies performed with PET gamma probes, two papers involved patients with heterogeneous malignancies. This category included the prospective study published in 2006 by Gulec et al. and involving 40 patients. The authors, after an accurate *in vitro* analysis of both sensitivity and spatial resolution, reported the successful identification of all [ $^{18}\text{F}$ ]FDG-PET-positive lesions, along with the detection of additional retroperitoneal foci and demonstrated the usefulness of the device in the re-exploration of the surgical bed after excision [15]. In 2009, Molinaa et al. confirmed the utility of using a PET gamma probe for navigating into scar tissue and for the confirmation of complete disease removal [26]. In 2010, Kim et al. published a pilot study involving 12 patients with differentiated thyroid cancer undergoing RGS with a PET gamma probe. The intraoperative device allowed the detection of all lesions demonstrated by preoperative PET, of additional sites in some patients, and a non-palpable, metastatic lymph node in the deep superior mediastinum not revealed by both PET and neck ultrasonography, after re-exploration of the operative bed [27]. Three patients with breast cancer were submitted to RGS with a PET gamma probe for both localization of primary tumors and evaluation of lymph node metastases by Orsaria and coworkers in a case series published in 2017 [28]. After a same-day PET scan performed before surgery, RGS confirmed preoperative findings in one patient, and localized additional nodal disease in another case, but showed low accuracy in the identification of nodal micrometastasis in the remaining patient. A PET gamma probe specifically designed for the detection of 511-keV photons released from the decay of  $^{18}\text{F}$  (Fig. 4) has been recently chosen by Rinehardt and colleagues in a prospective study involving pediatric patients with different cancers and published in 2022 [29]. As thoracic phantom models revealed an extremely low TBR, the PET gamma probe was not used for intraoperative navigation, but only for an external survey *ex vivo*.

### Gamma probes with electronic collimation

In 2010, de Jong and colleagues reported their experience of RGS in three patients with retroperitoneal testicular tumor recurrences [30]. The major concern in this setting of patients is represented by the presence of extensive scar tissue derived from previous surgery and often located in strict proximity to vital structures, making extremely difficult the discrimination between tumor and fibrosis, as well as surgeon's task. In one out of the three patients, the detector allowed for the localization and subsequent resection of an additional tumor with respect to preoperative imaging.

Subsequently, the use of an electronically collimated device enabled Vos and coworkers to identify and excise all suspicious clinically occult [ $^{18}\text{F}$ ]FDG accumulating lesions in nine consecutive patients with oncological, inflammatory, and infectious diseases [16]. A manuscript published in 2011 by García et al. focused on the role of preoperative [ $^{18}\text{F}$ ]FDG-PET imaging in selecting the better RGS procedure and concluded how in their cohort of patients positron-emitting radioguidance with an electronically collimated gamma probe, represented a valuable tool in case of multiple lesions not easily accessible for radioguided occult lesion localization (ROLL) [31].

### Discussion

Surgical resection represents the only curative treatment option for many patients with different malignancies. Unfortunately, a significant number of subjects may have undetected preoperative disease or residual low-volume tumor foci after surgery. Both of these conditions significantly affect complete tumor removal and thus prognosis. In this scenario, RGS offers the possibility of guiding the surgeon to the specific site of disease for targeted excision, enables the verification of complete removal by checking both resection margins and surgical bed, permits *ex vivo* assessment of disease eradication, and may allow the identification of additional foci not detected on preoperative imaging. Sentinel lymph node biopsy [32], radioguided occult lesion localization (ROLL) [33], minimally invasive radioguided parathyroidectomy (MIRP) [34], detection of neuroendocrine tumors [35], localization of neuroblastomas and pheochromocytomas [36, 37], radioguided seed localization (RSL) and radioimmunoguided surgery (RIGS) procedures [17, 38], represent the most common RGS applications with low and medium-energy gamma-emitting radionuclides. Since the last decades, PET imaging has played a key role in the management of different kinds of malignancies and has continuously evolved following the development of more sensitive detection systems, as well as the evolution of computerized image

**Table 2** Characteristics of gamma probes

Source	Probe	Type	Characteristics	Preclinical or phantom studies
Desai et al.	Neoprobe 1000model (Neoprobe Corporation, Dublin, OH)	Conventional gamma ray-sensitive probe	The detector portion of the instruments measures 11 mm in diameter and contains a cadmium-zinc-telluride crystal. External collimation was optimized with the use of an external shield placed over the detector portion of the probe (length 30 mm, diameter at base 28 mm, and diameter of aperture 0.8 mm). Lower energy window settings: 124, 150, and 200 keV; upper energy window kept constant at 255 keV	Adjustment of the lower window setting from 124 to 200 keV resulted in decrease in 2-s counts from 20,000 to 10,500 without shielding and from 6000 to 3000 when the shield was added. Additional studies with peritoneal phantom models showed that the probe was capable of detecting regions of high [ <sup>18</sup> F]FDG accumulation even against a homogeneous background signal and that shielding of tissues was possible with the use of readily available composite materials
Essner et al.	(C-Track, CareWise Medical, Morgan Hill, CA)	Conventional gamma ray-sensitive probe	NA	The probe was calibrated to accurately localize the point source of [ <sup>18</sup> F]FDG (~0.7 mCi/ml [ <sup>18</sup> F]FDG in 2 ml). The count rate was determined at variable distances from the probe set at various thresholds and energy windows to optimize the detection of the 511-keV energy. The probe was optimized with a set threshold energy of 490 keV and window of 20 keV. The probe was positioned at successive distances (0–10 cm) from the radiation source along a linear axis 90° from the point source. The FWHM measurement was optimized at 1.7 ± 0.1 cm using an energy threshold of 490 keV and a 20-keV window
Kraeber-Bodéré et al.	Modelo 2 Localization Monitor; Oris/Damri, Gif-sur-Yvette, France	Conventional gamma ray-sensitive probe	BgO scintillator	NP
Nwogu et al.	Gammed VI hand-held surgical gamma probe (Capintec, Ramsey NJ)	Conventional gamma ray-sensitive probe	NA	NP

Table 2 (continued)

Source	Probe	Type	Characteristics	Preclinical or phantom studies
Curtet et al.	-Modelo2 (Novelec, Grenoble, France) -GammaSup (Clerad, Clermont Ferrand, France)	Conventional gamma ray-sensitive probes	Bismuth germanate (BGO) crystal (15 mm thick, 5 mm in diameter), and a tungsten and lead alloy collimator (7 mm thick) not specifically collimated for the use of [ <sup>18</sup> F]FDG Thallium-activated caesium iodide (CsI(Tl)) scintillating crystal (10 mm thick, 7 mm in diameter) with a removable tungsten collimator 21 mm in diameter and 6 mm of thickness, designed to image 511-keV annihilation photons	FWHM from 0 to 20 mm depth: From 20.6 ± 0.4 mm to 55.3 ± 1.3 From 20.2 ± 1.2 mm to 40.6 ± 1.6 mm Sensitivity at 10 and 30 mm depth: From 814 to 241 s <sup>-1</sup> MBq <sup>-1</sup> in air and from 1,484 to 374 s <sup>-1</sup> MBq <sup>-1</sup> in water From 81 to 36 s <sup>-1</sup> MBq <sup>-1</sup> in air and From 27 to 16 s <sup>-1</sup> MBq <sup>-1</sup> in water Sensitivity through side shielding in air: 114 s <sup>-1</sup> MBq <sup>-1</sup> (14% of the signal at 10 mm depth) 2 s <sup>-1</sup> MBq <sup>-1</sup> (2% of the signal at 10 mm depth) SNR at, respectively, 10 and 30 mm depth: 88 and 22 131 and 76 NP NP NP
Sarikaya et al.	Neoprobe neo2000 unit (Neoprobe Corporation, Dublin, Ohio)	Conventional gamma ray-sensitive probe	NA	NP
Cohn et al.	Neoprobe neo2000 unit, Neoprobe Corporation, Dublin, Ohio	Conventional gamma ray-sensitive probe	NA	NP
Kaemmerer et al.	Gamma Finder (Silicon Sensor GmbH, Berlin, Germany)	Conventional gamma ray-sensitive probe	CsI(Tl) scintillation crystal (diameter: 4 mm, length: 8 mm) and a photodiode. Mechanical collimator of sintered tungsten material (TRIAMET: 90% tungsten with 10% nickel and iron, density 17 g/cm <sup>3</sup> ) with a wall thickness of 10 mm and a length of 32 mm. The lower energy window was set for 480 keV. Sensitivity of 1000 cps/MBq	NP
Sadowski et al.	Neoprobe hand-held gamma detector (model 2300; Neoprobe Corporation, Dublin, OH, USA)	Conventional gamma ray-sensitive probe	Detection capability at 511 keV with specific radionuclide selection/ high-energy gamma probe with detection capability at 511 keV with specific radionuclide selection	NP


Table 2 (continued)

Source	Probe	Type	Characteristics	Preclinical or phantom studies
Gulec et al.	PET-Probe (IntraMedical Imaging LLC, Los Angeles, CA)	PET gamma probe	The probe is designed to efficiently detect 511-keV photons of $^{18}\text{F}$ -labeled pharmaceuticals while having adequate directionality; it has a maximum thickness of 25 mm and a semi-conical tip with a 12 mm end diameter. The probe weighs 120 g and is easily handled by the surgeon	Using a probe set with a 20% window centered on 511 keV and a point source of 20 $\mu\text{Ci}$ $^{18}\text{F}$ , the probe recorded 28,800 and 5,100 counts per second at 0 and 1 cm in front of the probe tip, respectively. The sensitivity was determined to be 1440/second/ $\mu\text{Ci}$ at the probe tip and 255/second/ $\mu\text{Ci}$ at 1 cm. Analysis of the spatial resolution curve indicated an FWHM of 8 mm at the probe tip. Side penetration (the percentage ratio of the maximum count rate at the site to the maximum count rate at the tip) with a 1-mm point source and a 1-cm source were 1.3% and 3.4% for the probe's front and back sides, respectively
Molinaa et al.	PET probe Intramedical Imaging/GE, California	PET gamma probe	NA	NP
Kim et al.	NodeSeeker (GE Healthcare, Los Angeles, CA)	PET gamma probe	Probe diameter of 10 mm, shielding 33 mm in diameter and 30 mm in length, handle 15 mm in diameter with length of 170 mm	NP
Orsaria et al.	Care Wise Medical, Morgan Hills, CA, USA	PET gamma probe	Gadolinium oxorthosilicate crystal, 12.5 mm tungsten shielding; analyzer set for a photopeak of 511 keV, a window of 20%, and a threshold of 490 keV	NP
Rinehardt et al.	Neoprobe High Energy F-18 Probe (Mammotome, Cincinnati, OH, USA)	PET gamma probe	Internal shielding to enhance directionality	The probe was tested in a thoracic phantom model containing 6 spheres of variable diameters (0.7–2.0 cm) filled with a concentrated solution of [ $^{18}\text{F}$ ]FDG (24 kBq/ml). Measurements were performed both in absence of radioactive background and after filling the thoracic cavity with dilute [ $^{18}\text{F}$ ] FDG solution (6.0 kBq/ml) providing an SUV of 4 on PET-CT. Median TBR for the spheres was only 1.07 (range 1.06–1.11) at 110 min in dilute [ $^{18}\text{F}$ ] FDG background, indicating an inability of the PET probe to localize simulated lesions

**Table 2** (continued)


Source	Probe	Type	Characteristics	Preclinical or phantom studies
de Jong et al.	y Locator DXI, GF&E Tech GmbH, Seeheim, Germany	Gamma-probe with electronic collimation	NA	NP
García et al.	Gamma locator DXI GF&E	Gamma-probe with electronic collimation	Csl (TI) detector surrounded by 4 similar detectors	FWHM of the probe in the study with phantoms of 21.36 and 45 mm at a distance of 0.10 and 17 mm, respectively (R <sup>2</sup> : 0.9983)
Vos et al.	Y-locator DXI 511 (GFE, Darmstadt, Germany)	Gamma-probe with electronic collimation	Outer diameter: 23 mm, length: 38 mm, weight: 330 g. Five scintillation crystals are mounted as an upside-down pyramid, whose base is formed by a layer of semiconductor diodes and additional electronics. Sensitivity of 30 cps/kBq for 18F	NP

NA not applicable, NP not performed



**Fig. 3** PET/CT fusion image on transaxial section demonstrating a hypermetabolic lesion (SUVmax: 8.2) in the segment 6 of the liver (arrow), not detected by gamma probe. Final pathology was consistent with colorectal cancer metastasis

analysis and the diffusion of new radiopharmaceuticals. Among PET tracers, [<sup>18</sup>F]FDG represents the most effective imaging agent [39–41] having the advantage of being trapped inside malignant cancer cells, thus enhancing its use for tumor localization [42]. The uptake of [<sup>18</sup>F]FDG in most tumor tissues is based on the increased glycolytic rate. After entering tumor cells through glucose transporter-1 and 3 (GLUT 1 and GLUT 3) and undergoing phosphorylation to [<sup>18</sup>F]FDG-6-phosphate by hexokinase, [<sup>18</sup>F]FDG-6-phosphate accumulates due to slow dephosphorylation and to the fact that it cannot be utilized in the metabolic steps of glycolysis. <sup>18</sup>F molecule undergoes radioactive decay with slow release of β + particles (short range of 0.5–1.0 cm) and gamma rays which can travel several centimeters through tissue [43]. Different studies have demonstrated the superior sensitivity and specificity of [<sup>18</sup>F]FDG-PET imaging in comparison with other conventional techniques [44–46], making the possibility of extending its applications to RGS extremely appealing. Intraoperative radioguided resection of all [<sup>18</sup>F]FDG-positive tissue may ensure for more complete removal of the tumor burden as compared to the surgeons’ visual and hands-on approach of assessing and resecting presumed sites of tumor. In addition, intraoperative detection might help overcome the limitation of current generation PET systems in detecting small-volume disease [47]. The capability of a gamma probe to detect a lesion depends on several factors including the tumor avidity, the time from injection to probe survey, the clearance kinetics, the location of the lesion in particular in case of proximity to sites of physiologic uptake, and the technical characteristics of the probe, all ultimately determining surgery results.



**Fig. 4** PET probe system for clinical intraoperative use. **a** Hand-held probe capable of detecting high-energy photons, **b** neoprobe gamma detection system control unit with gamma counts per second (cps) readout (Mammotome, Cincinnati, OH, USA)

The first experiences of RGS with positron emitters date back to 20 years ago. To our knowledge, the most consistent RGS experience has been reported by Povoski et al. in a single-institution retrospective review involving 145 patients submitted to a multimodal imaging and detection approach to [ $^{18}\text{F}$ ]FDG directed surgery for known or suspected malignancies [48]. This work involves the largest cohort of patients until now and thus deserves to be mentioned even if not included in this systematic review due to the lack of specific technical data concerning intraoperative detection devices. Conventional gamma probes have been used for intraoperative detection of annihilation photons, but their performance remains below expectations. The major concern with applying currently available gamma probes for intraoperative localization of positron-emitting tracers is that these devices are not designed for the detection of the high-energy gamma rays derived from positron–electron annihilation (511-keV) but of low or medium-energy gamma rays such as 140–142 keV of technetium-99 m ( $^{99\text{m}}\text{Tc}$ ), 171 and 247 keV of indium-111 ( $^{111}\text{In}$ ), 159 keV of iodine-123 ( $^{123}\text{I}$ ), and 35 keV of iodine-125 ( $^{125}\text{I}$ ). The greatest obstacle to the use of these devices is theoretically represented by the rapid decay of the 511-keV photons to lower energy species which produces an artifact decreasing the directionality of probes. However, most published studies have demonstrated the usefulness of conventional surgical gamma-ray-sensitive probes for detecting the emission of the decay process of positron emitters, showing capabilities of detecting differences in radioactivity released from tumors and adjacent normal background in most cases and thus identifying most tumors demonstrated by preoperative PET. Moreover, in some papers, the use of conventional devices allowed for the identification of additional lesions, not revealed in preoperative PET scans. Nevertheless, some limitations have emerged from these studies, partially correlated with [ $^{18}\text{F}$ ]FDG properties, and partially to the characteristics of conventional gamma probes. A major limitation of [ $^{18}\text{F}$ ]FDG-PET imaging is represented by the

limited sensitivity for the detection of tumors showing a low metabolic activity [49]. As previously reported, Desai et al. failed in the identification of a recurrent mucin pseudomyxoma-producing tumor that is relatively acellular and presents few cells incorporating and metabolizing the [ $^{18}\text{F}$ ]FDG [17]. This tumor had been previously detected on PET imaging, but probably it changed from a cellular form to a mucinous debris one during the time interval between imaging and surgery. Such eventuality, may put the attention on the opportunity of performing preoperative imaging on the same day of surgery or, if not possible, to perform an additional acquisition of the surgical region immediately prior, as performed by Kaemmerer et al. [24]. Sarikaya and coworkers managed the identification of mucinous tumors with low uptake and previously visualized on preoperative PET scan, underlining how the surgeon's ability to position the intraoperative conventional gamma probe in close proximity to sites of suspected tumor recurrence, may ultimately make intraoperative detection more efficient, particularly in such cases [18]. In this regard, it is worth considering that the main advantage of intraoperative gamma probes over preoperative PET imaging is the ability to have the device in close proximity to the suspected site of disease, as demonstrated by Barber et al., who showed that a sodium iodide-based scintillation probe placed within 1 cm of the tumor was more sensitive in detecting small, deep lesions than a gamma camera [50]. Such considerations might explain the detection of a liver metastasis visualized on ultrasound but not found on preoperative imaging and not palpated on inspection, successfully performed by Essner et al. even in presence of high physiologic liver background [19]. Also of note is the fact that [ $^{18}\text{F}$ ]FDG is not cancer-specific, and resultant physiological uptake into benign tissue processes, such as infection and inflammation, may lead to false-positive findings, as shown by Nwogu et al. [22]. The authors also reported the difficulties in differentiating [ $^{18}\text{F}$ ]FDG activity signals of the primary tumor from those of peritumoral lymph nodes, thus leading to false-negative results and consequent understaging, eventually preventing patients from receiving adjuvant therapy. In both studies performed in patients with radioiodine-negative differentiated thyroid carcinoma, additional micrometastases not detected by both PET imaging and intraoperative conventional gamma probes were confirmed after histopathologic examination. Both papers underlined, however, the utility of conventional gamma probes in verifying the complete surgical resection of all detected foci [20, 21]. To further assess the surgical removal of known involved tissues, in their case series of three recurrent ovarian cancer patients, Cohn et al. performed a 10-min PET/CT scan of resected specimens and processed and reviewed images for the presence of hypermetabolic foci, prospecting the usefulness of immediate postoperative


patient PET imaging to confirm the absence of residual metabolic foci after resection [23]. As reported by Curtet and colleagues, the spatial resolution obtained with conventional gamma probes when detecting positron emitters is significantly much lower than reported in other studies with lower energy emitters, making it impossible to distinguish two foci located close to one another, specifically less than 2 cm with the conventional gamma probes compared in their study, thus potentially representing a dramatic drawback [5]. One of the major concerns with conventional gamma probes is represented by the achievement of satisfactory TBR, since they have small detectors, that detect only a fraction of 511-keV photons, and are equipped with side and back shieldings not designed to stop 511-keV, making them sensitive to radiation from both adjacent tissues and distant organs with high physiological activity. A minimum TBR of 1.5-to-1 has been suggested to make surgeons comfortable with targeted tissue localization [11, 15, 51]. However, different authors have underlined how it represents an arbitrary and fixed ratio potentially affected by several factors, including tumor tracer uptake, background activity, and type of detection probe system used for making counts per second measurements. Such considerations have lead Kraeber-Bodéré et al. to consider positive a TBR higher than 1.3 in their study for the detection of thyroid carcinoma metastases with a conventional gamma sensitive probe, owing to the high vascular background activity 1–2 h after [ $^{18}\text{F}$ ]FDG injection [20]. In an attempt to overcome the possible limitations of this fixed ratio method, the three-sigma statistical threshold criteria for gamma probe positivity, previously used for RIGS by Thurston and Burak [52–54], have been recently suggested by Chapman et al. to improve intraoperative in situ identification of [ $^{18}\text{F}$ ]FDG-avid sites [55]. According to this method, all examined areas with counts greater than 3 standard deviations above background counts should be considered abnormal tissue and excised. In a recent paper, Povoski et al. [52] reported the example of a gamma detection probe prototype that can greatly benefit from the three-sigma statistical threshold criteria, the K-alpha probe [56], a device that detects secondary, lower energy gamma emissions resulting when a thin metal foil plate, typically lead, is placed between a cadmium-zinc-telluride crystal and a source of gamma emission, such as [ $^{18}\text{F}$ ]FDG. The three-sigma statistical threshold criteria have also been chosen by Sarikaya and colleagues in their RGS study for the identification of FDG-avid tissues in colorectal cancer patients with a conventional gamma probe [18]. Recently, there has been the appearance of hand-held gamma probes specifically intended for attempting to detect 511-keV photons, generally referred to as PET probes. In their study performed in patients with heterogeneous malignancies, in largest part melanomas, Gulec and

colleagues managed to disclose target lesions in 11 patients with negative initial surgical exploration [15], and detect additional retroperitoneal lesions not seen in preoperative PET study through the use of a PET gamma probe. In accordance with most of the literature data, an in situ TBR of 1.5:1 or greater was considered a positive probe-detection criterion. The researchers separately reported the mean in situ TBR for melanoma, colon cancer, lymphoma, and breast cancer lesions as an individual type of tumor may present different [ $^{18}\text{F}$ ]FDG uptake. In 2009, Molina et al. performed an RGS study involving nine patients with different malignancies by successfully using a PET gamma probe to localize and remove [ $^{18}\text{F}$ ]FDG-avid lesions in the head and neck, chest, abdomen, and retroperitoneum [26]. Their results have been confirmed after adequate follow-up. Despite the use of a dedicated PET gamma probe, Kim et al. [27] were not able to establish a precise, meaningful cutoff of TBR and considered a value greater than 1.3 the positive threshold for differentiated thyroid cancer RGS, according to the previous work performed by Kraeber-Bodéré et al. with a conventional device [20]. Kraeber-Bodéré and colleagues also explained the necessity of correctly positioning the PET gamma probe perpendicularly on the suspected lesion to avoid TBR to decrease, thus leading to regrettable false-negative results. The problem of false-positive findings also represents a not negligible drawback in their setting of patients during evaluation of level II lymph nodes which are located close to the submandibular gland and pharynx, having a physiologically high [ $^{18}\text{F}$ ]FDG uptake. In their case series of three patients with breast cancer, Orsaria et al. [28] confirmed low accuracy in the detection of micrometastasis, in line with findings reported with conventional gamma probes [20, 22]. In a recent work, Rinehardt and colleagues reported a mean TBR of 1.07 in their thoracic phantom models, indicating an inability of the PET gamma probe to localize simulated lesions [29]. As in absence of a control arm, the preclinical phantom model was critical for probe validation, in their cohort of eight pediatric patients with primary, recurrent or metastatic cancers, the PET gamma probe was not used for intraoperative navigation, but only for an external survey ex vivo. It is clear that achieving satisfactory TBR remains a major concern, even with PET gamma probes specifically designed for the detection of annihilation photons. Attempts at improving current probe performances by increasing collimation to provide better spatial resolution and by creating crystal geometry of sufficient diameter and thickness to capture a higher percentage of photons would result in cumbersome devices prohibitively large, heavy, and expensive [3, 52, 56]. To overcome these physical barriers, engineering efforts have moved toward alternative directions. Innovative devices with active electronic collimation have been successfully applied to intraoperative hand-held gamma probe designs.

Such devices are represented by multi-detector systems able to focus on the target through the parametrization of the count rates of multiple scintillation crystals, not requiring mechanical collimation. In particular, the central crystal preferentially detects the activity of the lesion, while the concentric detector ring principally detects background activity. Thus, the electronic collimation locates the target through special algorithms. An innovative prototype based on these features and designed to overcome the limitations of passive collimators has been developed by the team of Sapienza (Fig. 5) [57] and recently tested for MIRP with positive results [58]. The same team also holds the latest Italian patent for a scintillation probe with active collimator specifically intended for laparoscopic applications (Italian patent application n102021000023963 PCT/IB2022/058698), positively evaluated at European level. In the field of RGS with positron emitters, Vos et al. in 2016 successfully used a multi-detector probe with 5 scintillation crystals to allow a definitive histopathological diagnosis in both oncologic patients and a subject with clinical signs of infection [16]. Previously, in a case series of three patients with retroperitoneal testicular tumor recurrences, De Jong and colleagues had, however, underlined how, despite electronic collimation outperforming traditional mechanical collimated probes, improving surgical resection margins in fibrotic areas remains difficult [30]. Similarly, Garcia et al. in a previous study on phantoms revealed how background interference continues to be the principal disadvantage even with these devices, and did not manage to intraoperatively locate all of the metabolically active lesions seen on PET scan [31]. Garcia and coworkers underlined the limitations of using a fixed TBR not accounting for both the specific study region and the depth of lesions, and put their attention on the timing between injection and intervention. As the metabolism of the [ $^{18}\text{F}$ ]FDG is different between normal tissues and tumors, with the latter presenting greater entrapment, TBR increases with time. However, to have a sufficient number of counts, the time window is 3–4 h in case of injection of 370 MBq, given the 110 min mean half-life time of  $^{18}\text{F}$ . The timing of tracer injection relative to surgical access of the target lesion is especially important in the setting of reoperations, as lysis of adhesions can take a long time before arriving at the target and may be

particularly critical when using radionuclides having a half-life significantly shorter than  $^{18}\text{F}$ . Such considerations have been reported by Sadowski and colleagues in their study performed on patients with GEP-NETs using a conventional gamma probe for the intraoperative detection of  $^{68}\text{Ga}$ -labeled somatostatin analogs, due to the 68 min half-life of [ $^{68}\text{Ga}$ ] Ga-DOTA peptides. Sadowski et al. reported high correct identification of gastric and small bowel neuroendocrine tumors, including mesenteric lymph nodes, but found a lower detection rate for primary pancreatic lesions and peripancreatic lymph nodes, as well as liver metastases [25]. Similarly, Kaemmerer and coworkers, successfully identified small lesions of 0.5 cm and more tumor foci as compared to both preoperative PET imaging and surgical palpation, using a conventional gamma probe for radioguidance [24]. Both studies underlined the usefulness of RGS in patients GEP-NETs presenting with scars and fibrosis from previous surgery but recognized some limitations in the detection capability due to high physiologic retention of radiopharmaceutical in the liver, kidney, spleen, and pancreas. At present, most literature data concerning RGS with positron emitters, regard procedures involving [ $^{18}\text{F}$ ]FDG, with only a limited experience with  $^{68}\text{Ga}$ -labeled somatostatin analogues. However, as PET with  $^{68}\text{Ga}$ -labeled somatostatin analogs has shown to be more accurate than other agents for detecting GEP-NETs and has gained an important role in the clinical management of GEP-NETs patients [59, 60], the possibility of using this radiotracer for RGS is extremely promising. Similarly, RGS procedures based on [ $^{18}\text{F}$ ]Fluorodihydroxyphenylalanine ([ $^{18}\text{F}$ ]FDOPA) uptake could represent an additional weapon against medullary thyroid carcinoma recurrences, as reported by Evangelista et al. [61] and subsequently shown in a case report by López-Gómez et al. [62]. We could assume that improved tissue specificity by novel radiolocalizing agents could provide highly specific intraoperative guidance. Overall, published studies demonstrated a consistent performance of intraoperative gamma probe detection over broadly dispersed tumor histologies, variable anatomic locations, including cervical, intra-abdominal, and intrathoracic operations, different settings of patients, from reoperations to pediatric subjects, and different intraoperative gamma detectors, from conventional devices,

**Fig. 5** The GonioProbe developed by the team of Sapienza. **a** GonioProbe prototype: current version, **b** current GonioProbe detection head: SiPM photodetector and detector assembly





to PET gamma probes and electronically collimated prototypes.

## Conclusion

Combining PET imaging with intraoperative radioguided approaches to detect positron-emitting radiopharmaceuticals should lead to significant improvements in surgeons' ability to obtain a complete resection of primary, recurrent or residual tumors. However, due to the nature of photons resulting from a positron–electron collision, acquiring a focused signal with gamma probes still remains extremely challenging and presents several critical issues. Despite the encouraging and favorable results, published studies have not provided sufficiently optimal evidence and RGS based on positron-emitting tracers has not gained a widespread use, being performed in only a scarcity of centers throughout the world. Changing PET tracers with gamma-emitting radionuclides [63] suitable for intraoperative radioguidance through low or medium-energy gamma probes represents a viable alternative option to correctly harvest pathologic tissue.

In the upcoming future, conducting further studies in larger cohorts, randomizing patients to operations with and without RGS, as well as performing long-term follow-up, could definitively determine the true value of gamma probe detection of positron emitters. Moreover, as advances in medicine are strictly related to advances in technology, technical improvements might determine if RGS with positron-emitting tracers will gain a routine established role in surgical practice.

**Author contributions** DFMS: literature search, literature review, and manuscript writing. FV: manuscript writing, editing and content planning. DSL: editing and content planning. FA: editing and content planning. DVG: editing and content planning. PR: editing and content planning.

**Funding** Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement. No funding has been received for this paper.

**Data availability** Not applicable.

## Declarations

**Conflict of interest** Maria Silvia De Feo, Viviana Frantellizzi, Luciano De Sio, Alessio Farcomeni, Giuseppe De Vincentis and Roberto Pani declare that have no conflict of interest.

**Ethical standards** This article does not contain any studies with human participants or animal subjects performed by any of the authors.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,

as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Rietbergen DD, Vano MN, Kleinjan GH, Brouwer OR, Valdes-Olmos RA, Vanl FW, Buckle T (2021) Interventional nuclear medicine: a focus on radioguided intervention and surgery. *Q J Nucl Med Mol Imaging* 65(1):4–19. <https://doi.org/10.23736/s1824-4785.21.03286-6>
- Selverstone B, Sweet WH, Robinson CV (1949) The clinical use of radioactive phosphorus in the surgery of brain tumors. *Ann Surg* 130(4):643–651
- Povoski SP, Neff RL, Mojzisek CM, O'Malley DM, Hinkle GH, Hall NC, Murrey DA Jr, Knopp MV, Martin EW Jr (2009) A comprehensive overview of radioguided surgery using gamma detection probe technology. *World J Surg Oncol* 7:11. <https://doi.org/10.1186/1477-7819-7-11>
- Hoffman EJ, Tornai MP, Janecek M, Patt BE, Iwanczyk JS (1999) Intraoperative probes and imaging probes. *Eur J Nucl Med* 26(8):913–935. <https://doi.org/10.1007/s002590050468>
- Zanzonico P, Heller S (2000) The intraoperative gamma probe: basic principles and choices available. *Semin Nucl Med* 30(1):33–48. [https://doi.org/10.1016/s0001-2998\(00\)80060-4](https://doi.org/10.1016/s0001-2998(00)80060-4)
- Bai B, Ruangma A, Laforest R, Tai YC, Leahy RM (2003) Positron range modeling for statistical PET image reconstruction. In: 2003 IEEE Nuclear Science Symposium. Conference Record (IEEE Cat. No.03CH37515), 19–25 Oct. 2003, vol 2504, pp 2501–2505. <https://doi.org/10.1109/NSSMIC.2003.1352400>
- Kwo DP, Barber HB, Barrett HH, Hickernell TS, Woolfenden JM (1991) Comparison of NaI(Tl), CdTe, and HgI<sub>2</sub> surgical probes: effect of scatter compensation on probe performance. *Med Phys* 18(3):382–389. <https://doi.org/10.1118/1.596683>
- Desai D, Arnold M, Saha S, Hinkle G, Soble D, Frye J, DePalatis L, Mantil J, Satter M, Martin E (1999) Intraoperative gamma detection of FDG distribution in colorectal cancer. *Clin Positron Imaging* 2(6):325. [https://doi.org/10.1016/s1095-0397\(99\)00085-0](https://doi.org/10.1016/s1095-0397(99)00085-0)
- Kuhn JA, Corbisiero RM, Buras RR, Carroll RG, Wagman LD, Wilson LA, Yamauchi D, Smith MM, Kondo R, Beatty JD (1991) Intraoperative gamma detection probe with presurgical antibody imaging in colon cancer. *Arch Surg* 126(11):1398–1403. <https://doi.org/10.1001/archsurg.1991.01410350092013>
- Bertsch DJ, Burak WE Jr, Young DC, Arnold MW, Martin EW Jr (1996) Radioimmunoguided surgery for colorectal cancer. *Ann Surg Oncol* 3(3):310–316. <https://doi.org/10.1007/bf02306288>
- Gulec SA, Hoenie E, Hostetter R, Schwartztruber D (2007) PET probe-guided surgery: applications and clinical protocol. *World J Surg Oncol* 5:65. <https://doi.org/10.1186/1477-7819-5-65>
- Maldonado A, González-Alenda FJ, Alonso M, Sierra JM (2007) PET-CT in clinical oncology. *Clin Transl Oncol* 9(8):494–505. <https://doi.org/10.1007/s12094-007-0093-5>
- Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G (2009) PET/CT for the staging and follow-up of patients with malignancies. *Eur J Radiol* 70(3):382–392. <https://doi.org/10.1016/j.ejrad.2009.03.051>

14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 6(7):e1000100. <https://doi.org/10.1371/journal.pmed.1000100>
15. Gulec SA, Daghighian F, Essner R (2016) PET-probe: evaluation of technical performance and clinical utility of a handheld high-energy gamma probe in oncologic surgery. *Ann Surg Oncol* 23(Suppl 5):9020–9027. <https://doi.org/10.1245/aso.2006.05.047>
16. Vos CG, Hartemink KJ, Muller S, Oosterhuis JW, Meijer S, van den Tol MP, Comans EF (2012) Clinical applications of FDG-probe guided surgery. *Acta Chir Belg* 112(6):414–418. <https://doi.org/10.1080/00015458.2012.11680864>
17. Desai DC, Arnold M, Saha S, Hinkle G, Soble D, Fry J, DePalatis LR, Mantil J, Satter M, Martin EW (2000) Correlative whole-body FDG-PET and intraoperative gamma detection of FDG distribution in colorectal cancer. *Clin Positron Imaging* 3(5):189–196. [https://doi.org/10.1016/s1095-0397\(00\)00052-2](https://doi.org/10.1016/s1095-0397(00)00052-2)
18. Sarikaya I, Povoski SP, Al-Saif OH, Kocak E, Bloomston M, Marsh S, Cao Z, Murrey DA, Zhang J, Hall NC, Knopp MV, Martin EW Jr (2007) Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer. *World J Surg Oncol* 5:80. <https://doi.org/10.1186/1477-7819-5-80>
19. Essner R, Hsueh EC, Haigh PI, Glass EC, Huynh Y, Daghighian F (2001) Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. *J Surg Res* 96(1):120–126. <https://doi.org/10.1006/jsre.2000.6069>
20. Kraeber-Bodéré F, Cariou B, Curtet C, Bridji B, Rousseau C, Dravet F, Charbonnel B, Carnaille B, Le Néel JC, Mirallié E (2005) Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. *Surgery* 138(6):1176–1182. <https://doi.org/10.1016/j.surg.2005.08.028>. (discussion 1182)
21. Curtet C, Carlier T, Mirallié E, Bodet-Milin C, Rousseau C, Barbet J, Kraeber-Bodéré F (2007) Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. *Eur J Nucl Med Mol Imaging* 34(10):1556–1562. <https://doi.org/10.1007/s00259-007-0393-6>
22. Nwogu C, Fischer G, Tan D, Glinianski M, Lamonica D, Demmy T (2006) Radioguided detection of lymph node metastasis in non-small cell lung cancer. *Ann Thorac Surg* 82(5):1815–1820. <https://doi.org/10.1016/j.athoracsur.2006.05.104>. (discussion 1820)
23. Cohn DE, Hall NC, Povoski SP, Seamon LG, Farrar WB, Martin EW Jr (2008) Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer. *Gynecol Oncol* 110(2):152–157. <https://doi.org/10.1016/j.ygyno.2008.04.026>
24. Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, Hommann M (2012) Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. *Clin Nucl Med* 37(2):142–147. <https://doi.org/10.1097/RLU.0b013e3182291de8>
25. Sadowski SM, Millo C, Neychev V, Aufforth R, Keutgen X, Glanville J, Alimchandani M, Nilubol N, Herscovitch P, Quezado M, Kebebew E (2015) Feasibility of radio-guided surgery with <sup>68</sup>Gallium-DOTATATE in patients with gastro-entero-pancreatic neuroendocrine tumors. *Ann Surg Oncol* 22(Suppl 3):S676–682. <https://doi.org/10.1245/s10434-015-4857-9>
26. Molina MA, Goodwin WJ, Moffat FL, Serafini AN, Sfakianakis GN, Avisar E (2009) Intra-operative use of PET probe for localization of FDG avid lesions. *Cancer Imaging* 9(1):59–62. <https://doi.org/10.1102/1470-7330.2009.0009>
27. Kim WW, Kim JS, Hur SM, Kim SH, Lee SK, Choi JH, Kim S, Choi JY, Lee JE, Kim JH, Nam SJ, Yang JH, Choe JH (2011) Radioguided surgery using an intraoperative PET probe for tumor localization and verification of complete resection in differentiated thyroid cancer: a pilot study. *Surgery* 149(3):416–424. <https://doi.org/10.1016/j.surg.2010.08.004>
28. Orsaria P, Chiaravalloti A, Fiorentini A, Pistolese C, Vanni G, Granai AV, Varvaras D, Danieli R, Schillaci O, Petrella G, Buonomo OC (2017) PET probe-guided surgery in patients with breast cancer: proposal for a methodological approach. *In Vivo* 31(1):101–110. <https://doi.org/10.21873/invivo.11031>
29. Rinehardt HN, Longo S, Gilbert R, Shoaf JN, Edwards WB, Kohanbash G, Malek MM (2022) Handheld PET probe for pediatric cancer surgery. *Cancers (Basel)*. <https://doi.org/10.3390/cancers14092221>
30. de Jong JS, van Ginkel RJ, Slart RH, Lemstra CL, Paans AM, Mulder NH, Hoekstra HJ (2010) FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences. *Eur J Surg Oncol* 36(11):1092–1095. <https://doi.org/10.1016/j.ejso.2010.08.129>
31. García JR, Fraile M, Soler M, Bechini J, Ayuso JR, Lomeña F (2011) PET/CT-guided salvage surgery protocol. Results with ROLL technique and PET probe. *Rev Esp Med Nucl* 30(4):217–222. <https://doi.org/10.1016/j.remnu.2011.02.011>
32. Alex JC, Krag DN (1993) Gamma-probe guided localization of lymph nodes. *Surg Oncol* 2(3):137–143. [https://doi.org/10.1016/0960-7404\(93\)90001-f](https://doi.org/10.1016/0960-7404(93)90001-f)
33. Bowles H, Sánchez N, Tapias A, Paredes P, Campos F, Bluemel C, Valdés Olmos RA, Vidal-Sicart S (2017) Radioguided surgery and the GOSTT concept: From pre-operative image and intraoperative navigation to image-assisted excision. *Rev Esp Med Nucl Imagen Mol* 36(3):175–184. <https://doi.org/10.1016/j.remnu.2016.09.004>
34. Norman J, Chheda H (1997) Minimally invasive parathyroidectomy facilitated by intraoperative nuclear mapping. *Surgery* 122(6):998–1003. [https://doi.org/10.1016/s0039-6060\(97\)90201-4](https://doi.org/10.1016/s0039-6060(97)90201-4). (discussion 1003–1004)
35. Ahlman H, Tisell LE, Wängberg B, Nilsson O, Fjälling M, Forsell-Aronsson E (1994) Somatostatin receptors on neuroendocrine tumors—a way to intraoperative diagnosis and localization. *Yale J Biol Med* 67(3–4):215–221
36. Filippi L, Valentini FB, Gossetti B, Gossetti F, De Vincentis G, Scopinaro F, Massa R (2005) Intraoperative gamma probe detection of head and neck paragangliomas with 111In-pentetreotide: a pilot study. *Tumori* 91(2):173–176. <https://doi.org/10.1177/030089160509100213>
37. Ricard M, Tenenbaum F, Schlumberger M, Travagli JP, Lumbroso J, Revillon Y, Parmentier C (1993) Intraoperative detection of pheochromocytoma with iodine-125 labelled meta-iodobenzylguanidine: a feasibility study. *Eur J Nucl Med* 20(5):426–430. <https://doi.org/10.1007/bf00209002>
38. Pouw B, de Wit-van der Veen LJ, Stokkel MP, Loo CE, Vrancken Peeters MJ, Valdés Olmos RA (2015) Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis. *J Surg Oncol* 111(2):185–191. <https://doi.org/10.1002/jso.23785>
39. Kole AC, Pruijm J, Nieweg OE, van Ginkel RJ, Hoekstra HJ, Schraffordt Koops H, Vaalburg W (1997) PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates. *J Nucl Med* 38(2):191–195
40. Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, Korkmaz M, Tansey W, Hicks K, Podoloff DA (1996) Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. *J Nucl Med* 37(9):1472–1476

41. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. *J Nucl Med* 34(3):414–419
42. Checkley S (1986) The brain, biochemistry and behavior. Proceedings of the Sixth Arnold O Beckman Conference in Clinical Chemistry. *J Neurol Neurosurg Psychiatry* 49(7):848. <https://doi.org/10.1136/jnnp.49.7.848-a>
43. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S (1991) 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. *Cancer* 67 (6):1544–1550. doi:[https://doi.org/10.1002/1097-0142\(19910315\)67:6<1544::aid-cnrcr2820670614>3.0.co;2-0](https://doi.org/10.1002/1097-0142(19910315)67:6<1544::aid-cnrcr2820670614>3.0.co;2-0)
44. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer GA (1999) Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. *Arch Surg* 134(5):503–511. <https://doi.org/10.1001/archsurg.134.5.503>. (discussion 511–503)
45. Gritters LS, Francis IR, Zasadny KR, Wahl RL (1993) Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. *J Nucl Med* 34(9):1420–1427
46. Damian DL, Fulham MJ, Thompson E, Thompson JF (1996) Positron emission tomography in the detection and management of metastatic melanoma. *Melanoma Res* 6(4):325–329. <https://doi.org/10.1097/00008390-199608000-00008>
47. Yamamoto S, Higashi T, Matsumoto K, Senda M (2006) Development of a positron-imaging detector with background rejection capability. *Ann Nucl Med* 20(10):655–662. <https://doi.org/10.1007/bf02984676>
48. Pivoski SP, Hall NC, Murrey DA Jr, Chow AZ, Gaglani JR, Bahnson EE, Mojzisek CM, Kuhrt MP, Hitchcock CL, Knopp MV, Martin EW Jr (2011) Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience. *World J Surg Oncol* 9:152. <https://doi.org/10.1186/1477-7819-9-152>
49. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE (2000) Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. *Dis Colon Rectum* 43(6):759–767. <https://doi.org/10.1007/bf02238010>. (discussion 767–770)
50. Barber HB, Barrett HH, Woolfenden JM, Myers KJ, Hicker-nell TS (1989) Comparison of in vivo scintillation probes and gamma cameras for detection of small, deep tumours. *Phys Med Biol* 34(6):727–739. <https://doi.org/10.1088/0031-9155/34/6/008>
51. Gulec SA (2007) PET probe-guided surgery. *J Surg Oncol* 96(4):353–357. <https://doi.org/10.1002/jso.20862>
52. Pivoski SP, Chapman GJ, Murrey DA Jr, Lee R, Martin EW Jr, Hall NC (2013) Intraoperative detection of <sup>18</sup>F-FDG-avid tissue sites using the increased probe counting efficiency of the K-alpha probe design and variance-based statistical analysis with the three-sigma criteria. *BMC Cancer* 13:98. <https://doi.org/10.1186/1471-2407-13-98>
53. Martin EW Jr, Thurston MO (1996) The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection. *Cancer Invest* 14(6):560–571. <https://doi.org/10.3109/07357909609076901>
54. Burak WE Jr, Boso M, Thurston MO, Martin EW (1996) Surgical applications of gamma-detecting probes. *Surg Technol Int* 5:259–264
55. Chapman GJ, Pivoski SP, Hall NC, Murrey DA Jr, Lee R, Martin EW Jr (2014) Comparison of two threshold detection criteria methodologies for determination of probe positivity for intraoperative in situ identification of presumed abnormal 18F-FDG-avid tissue sites during radioguided oncologic surgery. *BMC Cancer* 14:667. <https://doi.org/10.1186/1471-2407-14-667>
56. Martin EW, Chapman GJ, Subramaniam VV, Pivoski SP (2010) Intraoperative detection of gamma emissions using K-alpha X-ray fluorescence. *Expert Rev Med Devices* 7(4):431–434. <https://doi.org/10.1586/erd.10.33>
57. Pani R, Pellegrini R, Cinti MN, Longo M, Donnarumma R, D'Alessio A, Borrazzo C, Pergola A, Ridolfi S (2016) De Vincen-tis G Development of a novel gamma probe for detecting radiation direction. *J Instrumen*. <https://doi.org/10.1088/1748-0221/11/01/C01002>
58. Bononi M, Viviana F, De Feo MS, Sollaku S, Pani A, Falconi R, Pani R, Cavallaro G, Brozzetti S, De Vincentis G (2021) Gonioprobe, an innovative gamma-probe to guide parathyroid radioguided surgery: First clinical experiences with navigator and lock-on-target functions. *Curr Radiopharm* 14(2):161–169. <https://doi.org/10.2174/1874471013666200721013903>
59. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. *Neuroendocrinology* 95(2):120–134. <https://doi.org/10.1159/000335587>
60. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W (2014) Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. *Acta Radiol* 55(4):389–398. <https://doi.org/10.1177/0284185113496679>
61. Evangelista L, Farsad M, Piotta A, Pelizzo MR (2014) 18F-DOPA and 18F-FDG PET/CT, scintigraphic localization and radioguided surgery of recurrent medullary thyroid cancer: two case reports. *Curr Radiopharm* 7(2):133–137. <https://doi.org/10.2174/1874471007666141027151130>
62. López-Gómez J, Medina-Ornelas S, Salazar-Álvarez MA, Álvarez-Bojórquez M, Zaragoza-Cruz N, Melchor-Ruan J, Álvarez-Cano A (2018) Radioguided hepatic resection with (18)F-DOPA in a patient with metastatic medullary thyroid carcinoma. *Rev Esp Med Nucl Imagen Mol (Engl Ed)* 37(4):244–249. <https://doi.org/10.1016/j.rem.2017.12.003>
63. Filippi L, Palumbo B, Frantellizzi V, Nuvoli S, De Vincentis G, Spanu A, Schillaci O (2022) Prostate-specific membrane antigen-directed imaging and radioguided surgery with single-photon emission computed tomography: state of the art and future outlook. *Expert Rev Med Devices* 19(11):815–824. <https://doi.org/10.1080/17434440.2022.2146999>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.